Valuation: CorMedix Inc.

Market Cap 588M 508M 477M 434M 816M 56.2B 829M 5.59B 2.19B 28.14B 2.21B 2.16B 93.52B P/E 2026 *
15.5x
P/E 2027 * 126x
Enterprise Value 588M 508M 477M 434M 816M 56.2B 829M 5.59B 2.19B 28.14B 2.21B 2.16B 93.52B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 2.05x
Free-Float
93.07%
Yield 2026 *
-
Yield 2027 * -
1 day-7.37%
1 week+1.34%
Current month+0.13%
1 month-9.05%
3 months-0.13%
6 months+2.72%
Current year-35.17%
1 week 7.1
Extreme 7.1
8.98
1 month 7.1
Extreme 7.1
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Compliance Officer 66 2023-12-11
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Date Insider Type Main position Quantity % Market Cap.
2/4/26 Free

Chief Executive Officer

77,156 0.0979%
2/4/26 Free

General Counsel

36,006 0.0457%
2/4/26 Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
-7.37%+1.34%-41.69%+79.95% 588M
+0.21%+5.65%+61.31%+24.93% 335B
-2.29%-5.12%+21.64%-14.89% 68.61B
-2.00%-4.33%+46.66%+127.90% 11.2B
-0.91%-0.25%-2.89%-1.90% 8.49B
-0.34%+2.22%-13.22%-7.03% 4.84B
+1.45%+3.85%-26.84%+18.44% 4.42B
+0.32%-2.16%+0.82%+45.84% 4.28B
+2.57%+1.51%+13.28%+56.25% 2.81B
-1.59%-2.84%-4.94%-2.50% 2.19B
Average -0.99%-0.18%+5.41%+32.70% 44.26B
Weighted average by Cap. -0.25%+3.43%+50.51%+20.77%

Financials

2026 *2027 *
Net sales 337M 291M 274M 249M 468M 32.23B 476M 3.21B 1.25B 16.14B 1.27B 1.24B 53.64B 286M 247M 232M 211M 398M 27.39B 404M 2.72B 1.07B 13.72B 1.08B 1.05B 45.58B
Net income 45.66M 39.44M 37.06M 33.7M 63.36M 4.37B 64.41M 434M 170M 2.19B 171M 168M 7.27B 5.69M 4.91M 4.61M 4.2M 7.89M 544M 8.02M 54.07M 21.14M 272M 21.35M 20.88M 905M
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
26-08-14 US$7.540 -7.37% 2,701,417
26-08-13 US$8.140 +14.65% 6,069,943
26-08-12 US$7.100 -2.74% 1,353,419
26-08-11 US$7.300 -3.05% 1,182,274
26-08-10 US$7.530 +1.21% 842,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.540USD
Average target price
15.40USD
Spread / Average Target
+104.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock